Last update 23 Nov 2024
101-PGC-005
Last update 23 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms 101 PGC 005, 101PGC005, 101PGC005 (005) |
Target |
Mechanism GR antagonists(Glucocorticoid receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization  101 Therapeutics Ltd.Startup |
Active Organization 101 Therapeutics Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
7
Clinical Trials associated with 101-PGC-005A prospective, randomized, comparative, multi-centric, adaptive design clinical study to evaluate efficacy, safety and tolerability of 101-PGC-005 (‘005) for the treatment of moderate COrona VIrus Disease (Covid-19) disease patients. - NA
A Prospective, Randomized, Comparative, Multi-centric, Adaptive Design Clinical Study to Evaluate Efficacy, Safety, and Tolerability of 101-PGC-005 ('005) for the Treatment of Moderate Corona Virus Disease (COVID-19) Patients
A prospective, randomized, comparative, multi-centric, adaptive design clinicalstudy to evaluate efficacy, safety and tolerability of 101-PGC-005 (‘005) for the treatment of moderate COrona VIrus Disease (Covid-19) disease patients. - NA
100 Clinical Results associated with 101-PGC-005
Login to view more data
100 Translational Medicine associated with 101-PGC-005
Login to view more data
100 Patents (Medical) associated with 101-PGC-005
Login to view more data
100 Deals associated with 101-PGC-005
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| COVID-19 | Phase 2 | - |  101 Therapeutics Ltd.Startup | 26 Aug 2022 |
| Drug intoxication | Phase 1 | IN | 101 Therapeutics Ltd.Startup | 29 Oct 2022 |
| Post Acute COVID 19 Syndrome | Phase 1 | - | 101 Therapeutics Ltd.Startup | 26 Aug 2022 |
| Dengue | Preclinical | - | 101 Therapeutics Ltd.Startup | 26 Aug 2022 |
| HCoV-OC43 infection | Preclinical | - | 101 Therapeutics Ltd.Startup | 26 Aug 2022 |
| Leishmaniasis | Preclinical | - | 101 Therapeutics Ltd.Startup | 26 Aug 2022 |
| Zika Virus Infection | Preclinical | - | 101 Therapeutics Ltd.Startup | 26 Aug 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free